Behera et al. also reported that melanoma resistance to vemurafenib is driven by Wnt5A and that PPARγ activation with rosiglitazone upregulated the age-related protein klotho, a fibroblast growth factor-23 (FGF23) receptor, and decreased Wnt5A expression in therapy-resistant old melanoma patients, thus reducing tumor burden [74]. This evidence concerns the gene FGF23 and neoplasm.